Ganga Pharmaceuticals Ltd (GANGAPHARM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Ganga Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Un-audited Financial Results of the Company for the half year ended September 30, 2026
Financial Result · 02 Nov 2026, 10:21 pm
Ganga Pharmaceuticals Reports Half-Year Financial Results for Period Ended Sep'26 Ganga Pharmaceuticals posted revenue from operations of ₹141.63 lakhs for the half year ended 30th Sep'26, up 3.64% YoY from ₹136.65 lakhs. Total income reached ₹155.27 lakhs compared to ₹146.91 lakhs in the prior-year period. Net profit declined 66.18% YoY to ₹1.86 lakhs versus ₹5.50 lakhs, pressured by total expenses rising to ₹152.76 lakhs from ₹144.16 lakhs. Profit before tax stood at ₹2.52 lakhs, down from ₹3.35 lakhs YoY. Diluted EPS for the half-year period came in at ₹0.03.
Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Monday, November 02, 2026
Outcome · 02 Nov 2026, 10:10 pm
Ganga Pharmaceuticals Reports H1 FY27 Results with Profit Decline Ganga Pharmaceuticals posted revenue from operations of ₹141.63 lakh for the half-year ended 30th Sep'26, rising 3.6% YoY from ₹136.65 lakh in the corresponding period ended 30th Sep'25. Total income reached ₹155.27 lakh versus ₹146.91 lakh YoY. However, net profit dropped 66.2% YoY to ₹1.86 lakh compared to ₹5.50 lakh, pressured by higher raw material costs of ₹80.42 lakh and employee expenses of ₹32.72 lakh. Half-year basic and diluted EPS declined to ₹0.03 from ₹0.04 YoY.
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve inter-alia, the Un-audited ....
Intimation · 02 Nov 2026, 5:30 am
Ganga Pharmaceuticals Schedules Board Meeting for H1 FY27 Results Ganga Pharmaceuticals Limited announced that its Board of Directors will meet on 2nd Nov'26 to consider and approve the un-audited financial results for the half year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities has been closed for designated persons since 1st Oct'26 and will reopen 48 hours after the financial results are declared to the stock exchange.
Re-appointment of Managing Director
Change in Management · 27 Sept 2026, 2:06 am
Ganga Pharmaceuticals Approves Re-Appointment of Bharat Brijmohan Sharma as Managing Director Members of Ganga Pharmaceuticals Limited approved the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director at the 37th AGM held on 26th Sep'26. The re-appointment is for a three-year tenure effective 1st Apr'26, with the position not liable to retire by rotation. Mr. Sharma brings over 35 years of experience across the business and pharmaceutical sectors. Additionally, he is the spouse of Mrs. Srijna Sharma, Whole-time Director of the company, and is not debarred from holding directorial office by SEBI.
Voting Results of 37th Annual General Meeting along with the Scrutinizer Report
Annual General Meeting · 27 Sept 2026, 2:03 am
Proceeding of the AGM held on Saturday, September 26, 2026
Annual General Meeting · 27 Sept 2026, 12:45 am
The Company has sent Letter to the Shareholder for aGM whose Email Id is not resgistered with the RTA
Annual General Meeting · 02 Sept 2026, 1:26 am
Please find enclosed herewith the Notice of the AGM for F.Y. 2025-26
Annual General Meeting · 02 Sept 2026, 1:10 am
Please find enclosed herewith the Annual Report for F.Y. 2025-26
Others (Uncategorized) · 02 Sept 2026, 1:07 am
Intimation for 37th Annual General Meeting Schedule to be held on Saturday, September 26, 2026
Annual General Meeting · 02 Sept 2026, 12:59 am
Appointment of Secretarial Auditor
Change in Auditor · 21 May 2026, 10:26 pm
Ganga Pharmaceuticals Appoints Secretarial Auditor for FY26-27 Ganga Pharmaceuticals Limited announced its Board of Directors approved the appointment of M/s. D Maurya & Associates as the Secretarial Auditor for the financial year 2026-27. The appointment was made on 21 May'26, based on the Audit Committee's recommendation. M/s. D Maurya & Associates is a Mumbai-based proprietary firm established in 2010. There are no disclosed relationships between the appointee and the company's directors. This action complies with Regulation 30 of the SEBI Listing Regulations.
Appointment of Internal Auditor
Change in Auditor · 21 May 2026, 10:18 pm
Ganga Pharmaceuticals Appoints Deepak Jedhe & Co. as Internal Auditor Ganga Pharmaceuticals has appointed M/s. Deepak Jedhe & Co., Chartered Accountants, as its Internal Auditor for the financial year 2026-27. The appointment was approved by the Board of Directors on 21 May'26, following a recommendation from the Audit Committee. Deepak Jedhe & Co., founded in 2015, specializes in assurance, taxation, and advisory services. No relationships between the new auditor and the company's directors were disclosed. This appointment is made under Regulation 30 of the SEBI Listing Regulations.
Audited Financial Results of the Company for the half yeaar and financial year ended March 31, 2026
Financial Result · 21 May 2026, 10:04 pm
Ganga Pharmaceuticals FY26 Net Profit Rises 28.5% YoY, Driven by Revenue Growth Ganga Pharmaceuticals reported FY26 financial results, posting a Net Profit of Rs. 10.15 lakhs, a 28.5% YoY increase from Rs. 7.90 lakhs. Total Income for the year ended 31 Mar'26 grew modestly to Rs. 310.70 lakhs versus Rs. 307.33 lakhs YoY. For H2FY26, Net Profit rose to Rs. 7.67 lakhs from Rs. 5.50 lakhs in H2FY25. Full-year basic EPS improved to Rs. 0.17 from Rs. 0.16. The company also raised Rs. 112.88 lakhs through warrant conversions during the period.
Outcome of the Board Meeting held on May 21, 2026
Outcome · 21 May 2026, 9:55 pm
Ganga Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 146 (+10.2% YoY | +6.9% QoQ) ■ EBITDA: 6.2 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 4.2 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: 7.7 (+39.5% YoY | +209.3% QoQ) ■ EPS (INR): 0.13 (+85.7% YoY | +225.0% QoQ)
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Intimation · 21 May 2026, 5:30 am
Ganga Pharma Board Meeting on May 21, '26 for FY26 Financial Results Ganga Pharmaceuticals (BSE: 539680) has scheduled a Board of Directors meeting on May 21, '26. The agenda includes consideration and approval of the Audited Financial Results for the half-year and financial year ended Mar 31, '26. In line with insider trading regulations, the trading window for designated persons has been closed since Apr 01, '26. The window will reopen 48 hours after the financial results are publicly declared.
Re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director of the Company for a further period of Three year effective from April 01, 2026
Change in Management · 10 Mar 2026, 10:29 pm
Ganga Pharmaceuticals Re-appoints Managing Director for a Three-Year Term The Board of Directors of Ganga Pharmaceuticals approved the re-appointment of Mr. Bharat Brijmohan Sharma (DIN: 00077026) as Managing Director. The new three-year term is effective from 01 Apr'26, subject to shareholder approval. Mr. Sharma, who has over 35 years of experience in the business and pharma industry, is not liable to retire by rotation. He is the spouse of Mrs. Srijna Sharma, a Whole-time Director. The Board meeting on 10 Mar'26 confirmed the re-appointment based on committee recommendations.
Re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director for a further period of Three years effective from April 01, 2026
Change in Management · 10 Mar 2026, 10:21 pm
Ganga Pharma Re-appoints Bharat Sharma as Managing Director for Three Years Ganga Pharmaceuticals Limited's board approved the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director on 10 Mar'26. The new three-year term is effective from 01 Apr'26, subject to member approval. Mr. Sharma, with over 35 years of experience in the pharma industry, is not liable to retire by rotation. The company confirmed he is not debarred by SEBI or any other authority. He is the spouse of Mrs. Srijna Sharma, a Whole-time Director of the company.
Statement of Deviation or Variation for the half year ended September 30, 2025
Others (Uncategorized) · 08 Nov 2025, 12:57 am
Statement of Deviation or Variation for the half year ended September 30, 2025
Others (Uncategorized) · 07 Nov 2025, 10:51 pm
Un-audited financial results of the Company for the half year ended on September 30, 2025
Financial Result · 07 Nov 2025, 8:26 pm
Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Friday, November 07, 2025
Outcome · 07 Nov 2025, 8:19 pm
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 07 Nov 2025, 5:30 am
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavesh Dhirajlal Tanna
Acquisition/ Disposal of Shares · 22 Sept 2025, 6:38 pm
Proceedings and Voting Results along with the Scrutinizer Report of 36th Annual General Meeting of Ganga Pharmaceuticals Limited held on Saturday, September 20, 2025
Annual General Meeting · 21 Sept 2025, 12:32 am
Proceeding and Voting Results of the 36th Annual General Meeting (AGM) of Ganga Pharmaceuticals Limited (the Company) held on Saturday, September 20, 2025
Annual General Meeting · 21 Sept 2025, 12:23 am